Site Under Development, Content Population and SEO, Soft Launch 1st January 2020

Medical Business Data
Presented by
Staff Writer, TMN  Jul 04, 2018
The US Food and Drug Administration (FDA) has approved updated labeling for Keytruda (pembrolizumab; Merck) and Tecentriq (atezolizumab; Genentech) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy. The  USFDA is continuing to review Merck's Keytruda and Roche's Tecentriq in pr...